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ABSTARCT
Objective: The present study envisage a series of sparfloxacin derivatives were synthesized (Q1-Q10) with added derivatives such as aminomethyl 
benzenesulfenyl, methyl (methylamino)benzenesulfenyl, amino methyl benzoyl chloride, nitromethyl benzoyl chloride, dimethyl phenylamino, 
methoxymethyl phenylamino, dimethyl oxopyrazol, methyl dioxopyrrolidine, methyl oxopyrrolidine, and N-Boc amino methyl methylpyrrolidine 
through N-Piperzinyl linkage.
Methods: All the newly synthesized compounds were characterized by infrared,1H nuclear magnetic resonance, mass spectrometry, and elemental 
analysis technique, screened for docking stimulation to find out binding modes of synthesized derivatives with 3FV5 and 3IMW, and evaluated for 
in vitro antimicrobial activity.
Results: From this study, it was found that the compound Q5 showed good antibacterial activity against Gram-positive (Staphylococcus aureus) and 
compound Q4 showed good antibacterial activity against Gram-negative (Escherichia coli) in comparison with standard drugs (ciprofloxacin and 
sparfloxacin). The zone of inhibition and minimum inhibitory concentrations studies performed to synthesized compounds. The correlation between 
experimental data (minimum inhibitory concentrations) and docking score suggests that penetration for docking simulation is good to mild in 
reproducing experimental orientation of these synthesized compounds.
Conclusion: The analogs of sparfloxacin are suggested to be potent inhibitors with sufficient scope for further exploration.
Keywords: N-Piperzinyl derivatives, Ciprofloxacin, Sparfloxacin, DNA gyrase, Topoisomerase-IV, Docking studies.
INTRODUCTION
Quinolones have become a major class of antibacterial agents; they 
have an attraction because of their extremely potent activity, rapid 
bactericidal effects, and low incidence of resistance development.The 
main disadvantage of the quinolones is their limited activity against Gram-
positive pathogens and methicillin-resistant Staphylococcus aureus [1,2]. 
In addition, quinolones can cause adverse effects, such as central nervous 
system effects, phototoxicity, tendonitis, hypoglycemia, and serious cardiac 
dysrhythmias [3,4]. Thus, despite many advances in the fluoroquinolones 
field, there exists continuous need for novel quinolones with better activity 
profile, pharmacokinetics, and tolerability, to overcome the limitation of 
existing drugs.The new generations of fluoroquinolones achieved significant 
improvement in potency, spectrum and physicochemical properties [5,6]. 
The structure-activity relationship studies revealed that the fluorine atom 
and the 1-alkyl, 1,4-dihydro-4-oxo-quinolone-3-carboxylic acid skeleton 
of fluoroquinolones are responsible for potency represented in binding 
with topoisomerase-II DNA gyrase and topoisomerase IV enzymes [7-9]. 
Topoisomerase II is a target for a variety of quinolones-based drugs. High 
activity against the eukaryotic type II enzyme is exhibited by drugs contains 
aromatic substituents at their C-7 position [10].
Sparfloxacin is a fluoroquinolones antibacterial agent active against 
Gram-positive and Gram-negative bacteria [11]. It has a controversial 
safety profile and about 37–45% bound to protein in the blood [12,13]. 
Its structure and ball-stick three-dimensional model have shown in 
Figs.1 and 2, respectively.
Skin penetration of sparfloxacin is good. The skin/Plasma ratio 
was about 1.00 at 4h (time of peak plasma concentration) 
and 1.39 at 5h [14]. The compound is used for treating community-
acquired lower respiratory tract infection (acute sinusitis, exacerbations 
of chronic bronchitis caused by susceptible bacteria, and community-
acquired pneumonia) [15-17].
The present study reports on the synthesis, spectroscopic analysis 
including IR and1H NMR, mass spectrometry and their biological 
activities of N-piperazinyl derivatives of sparfloxacin (Q1-Q10).
Molecular docking plays an important role in the rational design of 
drugs. In the field of molecular modeling, docking is a method which 
predicts the preferred orientation of one molecule to a second when 
bound to each other to form a stable complex. Molecular docking can 
be defined as an optimization problem, which would describe the 
“best-fit” orientation of a ligand that binds to a particular protein of 
interest [18,19]. The main aim is to evaluate the possible relationship 
between docking activity of the synthesized compounds (Q1-Q10) along 
with interaction with the crystal structure of DNA gyrase of S. aureus 
[PDB:5IWM] and topoisomerase-IV of Escherichia coli [PDB ID: 3FV5].
METHODS
Experimental





1,4-dihydro-4-oxoquinoline-3-carboxylic acid, (compound Q7) 
5-amino-1-cyclopropyl-6,8-dif luoro-1,4-dihydro-7-(4-(4,5-
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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dihydro-3,4-dimethyl-5-oxopyrazol-1-yl)-3,5-dimethylpiperazin-
1-yl)-4-oxoquinoline-3-carboxylic acid, (compound Q8) 
5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(3,5-dimethyl-4-
(3-methyl-2,5-dioxopyrrolidin-1-yl)piperazin-1-yl)-4-oxoquinoline-3-
carboxylic acid, (compound Q9) 5-amino-1-cyclopropyl-6,8-difluoro-
1,4-dihydro-7-(3,5-dimethyl-4-(3-methyl-2-oxopyrrolidin-1-yl)
piperazin-1-yl)-4-oxoquinoline-3-carboxylic acid and (compound 
Q10) 5-amino-7-(4-(3-(aminomethyl)-4-methylpyrrolidin-1-yl)-
3,5-dimethylpiperazin-1-yl)-1-cyclopropyl-6,8-difluoro-1,4-
dihydro-4-oxoquinoline-3-carboxylic acid from Sparfloxacin 
(5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(3,5-dimethyl 
piperazin-1-yi)-4-oxoquinoline-3-carboxylic acid):
To an equimolar amino methyl benzenesulfenyl (derivative Q1) 
methyl (methylamino)benzenesulfenyl (derivative of Q2), dimethyl 
oxopyrazol (derivative of Q7), methyl dioxopyrrolidine (derivative of 
Q8), methyl oxopyrrolidine (derivative of Q9), N-Boc amino methyl 
methylpyrrolidine (derivative of Q10), and sparfloxacin were added 
to ethanol, required quantity of formaline (37%) was added, and the 
reaction mixture was heated at reflux overnight, cooled. The resulting 
precipitated solid was filtered and recrystallized from 95% ethanol 
(100 ml) to give the product.
Procedure for synthesis of (compound Q3) 7-(4-(4-amino-3-
methylbenzoyl)-3,5-dimethylpiperazin-1-yl)-5-amino-1-cyclopropyl-6,8-





To an equimolar mixture of finely powdered amino methyl benzoyl 
chloride (derivative of Q3), nitromethyl benzoyl chloride (derivative 
of Q4) and sparfloxacin were dissolved in 5% NaOH solution mix 
vigorously. The reaction mixture was warmed for an hour and allowed 
to cool for crystallization. The precipitate was filtered off, washed and 
dried under vacuum in a desiccator. Sparfloxacin reacts with derivatives 
in the presence of THF and TEA.





dihydroquinoline-3-carboxylic acid from Sparfloxacin (5-amino-
1 - c yc l o p ro py l - 6 , 8 - d i f l u o ro - 1 , 4 - d i hyd ro - 7 - ( 3 , 5 - d i m e t hy l 
piperazin-1-yi)-4-oxoquinoline-3-carboxylic acid):
To an equimolar mixture of sparfloxacin and sodium bicarbonate in 10ml 
of acetonitrile was stirred at 50°C for 4 h reaction mixture was cooled to 
0°C and dimethyl phenyl amino (derivative of Q5) and methoxy methyl 
phenyl amino (derivative of Q6) were added. The mixture was stirred at 
magnetic stirrer for 5 h at 0–5°C acetonitrile was removed, the precipitate 





IR Vmax (cm−1ATR): 3530.6 (N-H), 3051.18 (CH Ar.), 3034.27 (CH 
cyclopropane), 2619.52 (O-H carboxyl), 1704.80 (C=O carboxyl), 
1622.98 (C=C), 1383 (SO2-Piperazine), 1342.61 (C-F), 1270.93 (C-N).1H 
NMR (300 MHz; DMSO-d6) δ:1.075–1.33 (m,4H, Cyclopropane), 1.11 
(m,6H, methyl), 2.12(s,3H,methyl), 2.68(m,2H,methine), 3.2-3.5(q, 4H, 
methylene), 4.12(m, 1H, cyclopropane), 6.62 (s, 2H, amine), 6.96–7.24 
(d, 3H, benzene), 7.51 (s, 2H,amine), 8.01 (s, 1H, ethylene), 15.12 (s, 1H, 
Carboxylic acid). MS-ESI: m/z 545.19 (M+1), elemental analysis (%): 




IR Vmax (cm−1ATR): 3302.34(N-H), 2920.20 (CH), 2805 (O-H carboxyl), 
1442.49 (C=C), 1342.61 (SO2-Piperazine), 1256.41 (C-N), 1088.94 
(C-F).1H NMR (300 MHz; DMSO-d6) δ:1.075–1.33 (m,4H, Cyclopropane), 
1.11 (m,6H, methyl), 2.12 (s,3H, methyl), 2.68 (m,2H, methine), 3.2–3.5 
(q, 4H, methylene), 4.12 (m, 1H, cyclopropane), 6.62 (s, 2H, amine), 
6.96–7.24 (d, 3H, benzene), 7.24 (m, 2H, benzene), 7.51 (s, 2H, amine), 
8.01 (s, 1H, ethylene), 15.12 (s, 1H, carboxylic acid). MS-ESI: m/z 555.18 
(M+1), elemental analysis (%): C27H31F2N5O4S: C, 57.24; H, 5.36; F, 6.96; 




IR Vmax (cm−1ATR): 3370.87 (N-H), 3033.93 (CH Ar.), 2978.10 (O-H 
carboxyl), 2923.14 (C-H cyclopropane), 1703.94 (C=O carboxyl), 1627.27 
(C=C), 1367.51 (SO2-Piperazine), 1288 (N-H sec amine), 1265.08 (C-
N), 1088.93 (C-F).1H NMR (300 MHz; DMSO-d6) δ:1.075-1.33 (m,4H, 
Cyclopropane), 1.31 (m,6H, methyl), 2.12 (s,3H, methyl), 3.465–3.71 
(m,4H, methylene), 3.65 (m, 2H, methine), 4.12 (m, 1H, cyclopropane), 
6.62 (s, 2H, amine), 6.93 (d, 1H, benzene),7.44 (d, 1H, benzene), 7.51 
(s, 2H, amine), 7.66 (s,1H, benzene), 8.66 (s, 1H, ethylene), 14.93 (s, 1H, 
carboxylic acid). MS-ESI: m/z 525.22 (M+1), elemental analysis (%): 
C27H29F2N5O4: C, 61.71; H, 5.56; F, 7.23; N, 13.33; O, 12.18.
Q4: 7-(4-(4-nitro-3-methylbenzoyl)-3,5-dimethylpiperazin-1-yl)-
5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxoquinoline-
Fig. 1: Sparfloxacin [5-amino-1-cyclopropyl-6,8-difluoro-1,4-
dihydro-7-(3,5-dimethyl piperazin-1-yi)-4-oxoquinoline-3-
carboxylic acid]
Fig. 2: Sparfloxacin (ball and stick three-dimensional model)
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3-carboxylic acid
IR Vmax (cm−1ATR): 3069.64 (CH Ar.), 2871.71 (CH cyclopropane), 
2725.33 (O-H carboxyl), 1679.00 (C=O carboxyl), 1416.37 (C=C), 
1322.22 (C-F), 1272.36 (C-N).1H NMR (300 MHz; DMSO-d6) δ:1.075–
1.33 (m,4H, Cyclopropane), 1.31 (m,6H, methyl), 2.64 (s,3H, methyl), 
3.465-3.71 (m,4H, methylene), 3.65 (m, 2H, methine), 4.12 (m, 1H, 
cyclopropane), 6.62(s, 2H, amine), 8.01 (d, 1H, benzene), 8.07 (s, 
1H, benzene), 8.30 (d, 1H, benzene), 8.66 (s, 1H, ethylene), 14.93 (s, 
1H, carboxylic acid). MS-ESI: m/z 559.19 (M+1), elemental analysis(%): 




IR Vmax (cm−1ATR): 3370.32(N-H), 3095.32 (CH Ar.), 2916.52 (C-H 
cyclopropane), 2652.54 (O-H carboxyl), 1665.33 (C=C), 1628.25 (C=O 
carboxyl), 1332.30 (C-F), 1271.09 (C-N).1H NMR (300 MHz; DMSO-d6) 
δ:1.075–1.33 (m,4H, Cyclopropane), 1.27 (m,6H, methyl), 2.19–2.21 
(d,6H, methyl), 2.88 (m,2H, methine), 3.285–3.54 (q, 4H, methylene), 
4.12 (m, 1H, cyclopropane), 6.62 (s, 2H, amine), 6.75–691 (d, 2H, 
benzene), 6.92 (d, 1H, benzene), 8.66 (s, 1H, ethylene), 8.78 (s,1H, 
sec amine), 14.93 (s, 1H, carboxylic acid). MS-ESI: m/z 511.24 (M+1), 





IR Vmax (cm−1ATR): 3069.44 (C-H cyclopropane), 2946.43 (CH Ar.), 
2871.73(O-H carboxyl), 2842.41 (OCH3), 1678.12 (C=O carboxyl), 
1415.77 (C=C), 1272.00 (C-N), 1069.39 (C-F).1H NMR (300 MHz; 
DMSO-d6) δ: 1.075–1.33 (m,4H, Cyclopropane), 1.27 (m,6H, methyl), 
2.15 (s,3H, methyl), 2.88 (m,2H, methine), 3.28–3.54 (q, 4H, methylene), 
3.72 (s,3H, methyl), 4.12 (q, 1H, cyclopropane), 6.62(t, 2H, amine), 
6.65–6.80 (d, 2H, benzene), 6.92(s, 1H, benzene), 8.66 (s, 1H, ethylene), 
8.78 (s,1H, sec amine), 14.93 (s, 1H, carboxylic acid). MS-ESI: m/z 
527.23 (M+1), elemental analysis (%): C27H31F2N5O4: C,61.47; H, 5.92; 




IR Vmax (cm−1ATR): 3311.85 (N-H), 3057.23 (CH Ar.), 2933.28 (C-H 
cyclopropane), 2844.14(O-H carboxyl), 1625.38(C=O carboxyl), 
1477.71(C=C), 1256.33(C-N), 1089.42(C-F).1H NMR (300 MHz; 
DMSO-d6) δ: 0.70 (d,3H, methyl), 1.075–1.33 (m,4H, Cyclopropane), 
1.27 (m,6H, methyl), 1.94 (s,3H, methyl), 2.5 (q,1H, methine), 2.88 (m, 
2H, methine), 3.28–3.54 (q,4H, methylene), 4.12 (m, 1H, cyclopropane), 
6.62 (s, 2H, amine), 8.66 (s, 1H, ethylene), 14.93 (s, 1H, carboxylic 
acid). MS-ESI: m/z 502.41 (M+1), elemental analysis (%): C24H28F2N6O3: 




IR Vmax (cm−1ATR): 3373.50 (N-H), 3084.24 (CH Ar.), 2915.38 (O-H 
carboxyl), 1628.46 (C=O carboxyl), 1470.32 (C=C), 1217.17 (C-N), 
1025.73 (C-F).1H NMR (300 MHz; DMSO-d6) δ: 1.075–1.33 (m,4H, 
Cyclopropane), 1.17 (d,3H, methyl), 1.27 (m,6H, methyl), 2.61–2.85 
(m,3H, succinimide), 2.88 (m,2H, methane), 3.28–3.54 (q,4H, methylene), 
4.12 (m, 1H, cyclopropane), 6.62 (s, 2H, amine), 8.66 (s, 1H, ethylene), 
14.93 (s, 1H, carboxylic acid). MS-ESI: m/z 505.90 (M+1), elemental 




IR Vmax (cm−1ATR): 3377.55 (N-H), 3084.48 (CH Ar.), 2849.11 (C-H 
cyclopropane), 2687.43 (O-H carboxyl), 1703.90 (C=O carboxyl), 
1622.59 (C=C), 1342.49 (C-F), 1270.55 (C-N).1H NMR (300 MHz; 
DMSO-d6) δ: 1.075–1.33 (m,4H, Cyclopropane), 1.12 (d,3H, methyl), 1.27 
(m,6H, methyl), 1.91–2.17 (m,2H,pyrrolidine), 2.33 (m,1H, pyrrolidine-
2-one), 2.88 (m, 2H, methine), 3.24–3.34 (m,2H,pyrrolidine-2-one), 
3.28–3.54 (q,4H, methylene), 4.12 (m, 1H, cyclopropane), 6.62 (s, 2H, 
amine), 8.66 (s, 1H, ethylene), 14.93 (s, 1H, carboxylic acid).MS-ESI: 
m/z 489.22 (M+1), elemental analysis(%): C24H29F2N5O4: C,58.59; H, 




IR Vmax (cm−1ATR): 3382.18 (N-H), 3084.70 (CH Ar.), 3100 (C-H 
cyclopropane), 2915.29 (O-H carboxyl), 1660.31 (C=O carboxyl), 
1405.09 (C=C), 1332.37 (C-F), 1271.72 (C-N).1H NMR (300 MHz; 
DMSO-d6) δ: 0.93 (d,3H, methyl), 1.075–1.33 (m,4H, Cyclopropane), 
1.27 (m,6H, methyl), 1.5 (m,2H,amine), 1.44 (s,1H,pyrrolidine), 
1.59 (m,1H,pyrrolidine), 2.44–2.69 (q,2H, methylene), 2.6–2.81 
(q,4H,pyrrolidine), 2.88 (m, 2H, methine), 3.28–3.54 (q,4H,methylene), 
4.12 (m, 1H, cyclopropane), 6.62 (s, 2H, amine), 8.66 (s, 1H, ethylene), 
14.93 (s, 1H, carboxylic acid). MS-ESI: m/z 504.27 (M+1), elemental 
analysis(%): C25H34F2N6O8: C,59.51; H, 6.79; F, 7.53; N, 16.66; O, 9.51.
Biological evaluations
Antimicrobial activity
All the title compounds were screened for their antibacterial and 
antifungal activities. The antibacterial activity of the synthesized 
compounds was tested against two Gram-positive bacteria (S. aureus 
ATCC 6438P and Staphylococcus epidermidis ATCC 155) and two Gram-
negative bacteria (E. coli ATCC 25922 and Klebsiella pneumoniae ATCC 
29665) using nutrient agar medium. The antifungal activities of the 
compounds were tested against two fungi, namely Aspergillus niger 
ATCC 9029 and Aspergillus fumigatus ATCC 46645 using Sabouraud 
dextrose agar. For preliminary screening, the antimicrobial tests were 
carried out by the paper disc diffusion method. The minimum inhibitory 
concentrations (MIC) of the compounds were also determined by agar 
streak dilution method.
Paper disc diffusion technique
The sterilized [20] (autoclaved at 120°C for 30 min) medium (40–50°C) 
was inoculated (1 ml/100 ml of medium) with the suspension (105 
cfu/ml) of the microorganism (matched to McFarland barium sulfate 
standard) and poured into a Petri dish to give a depth of 3–4 mm. 
The paper impregnated with the test compounds (100 µg/ml in 
dimethylformamide) was placed on the solidified medium. The plates 
were pre-incubated for 1 h at room temperature and incubated at 37°C 
for 24 and 48 h for antibacterial and antifungal activities, respectively. 
Ciprofloxacin (100 µg/disc) and ketoconazole (100 µg/disc) were used 
as a standard for antibacterial and antifungal activities, respectively. 
The observed zone of inhibition is presented in Table 1.
MIC
MIC [21] of the compound was determined by agar streak dilution 
method. A stock solution of the synthesized compound (100 µg/ml) 
in dimethylformamide was prepared, and graded quantities of the 
test compounds were incorporated in a specified quantity of molten 
sterile agar (nutrient agar for antibacterial activity and Sabouraud 
dextrose agar medium for antifungal activity). A specified quantity of 
the medium (40–50°C) containing the compound was poured into a 
Petri dish to give a depth of 3–4 mm and allowed to solidify. Suspension 
of the microorganism was prepared to contain approximately 
105 cfu/ml and applied to plates with serially diluted compounds in 
dimethylformamide to be tested and incubated at 37°C for 24 h and 
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48 h for bacteria and fungi, respectively. The MIC was considered to 
be the lowest concentration of the test substance exhibiting no visible 
growth of bacteria or fungi on the plate. The observed MIC is presented 
in Table 1.
Molecular docking studies of sparfloxacin
Molecular docking studies of synthesized compounds Q1-Q10 with well-
established structure of S. aureus and E. coli were performed using Auto 
Dock vina 1.12 version and chimera 1.12 version. The binding pocket of 
the active site of DNA gyrase (PDB: 5IWM) for Gram-positive bacteria 
like S. aureus and (PDB: 3FV5) for Gram-negative bacteria like E. coli. 
Docking method involves the following steps. First, the ligand molecule 
was build, in the second step required protein was downloaded 
from PDB, preparation, and validation of macromolecule by X-ray 
crystallography. Third step is the identification of binding affinity by the 
extent of binding of a ligand to the protein of molecule.
RESULTS AND DISCUSSION
Chemistry
The synthetic route to obtain the necessary derivative from commercially 
available reagent is briefly outlined in Scheme 1. The synthesized 
compounds (Q1-Q10) were obtained with the help of various derivatives 
and reagents such as formaline (37%), 5% NaOH, Na2CO3, and acetonitrile. 
All reactions of synthesized compounds occurred with optimum 
temperature. The structure of all synthesized compounds was confirmed 
by IR,1HNMR, and mass spectral elemental analysis techniques.
Antibacterial activity
All the synthesized compounds (Q1-Q10) were tested zone of inhibition and 
MIC values against two Gram-positive (S. aureus and S. epidermidis) and 
two Gram-negative (E. coli and K. Pneumonia) bacteria. All the compounds 
exhibited mild to moderate activity against both Gram-positive and Gram-
negative bacteria. Compounds Q5, Q6, Q4, and Q3 were found to possess 
significant antibacterial activity against Gram-positive organisms when 
compared to standard drugs (ciprofloxacin and sparfloxacin). Compounds 
Q4, Q8, Q9, and Q10 were found to possess significant antibacterial activity 
against Gram-negative organisms when compared to standard drugs 
(ciprofloxacin and sparfloxacin). The synthesized compounds exhibited 
MIC values in the range of 0.8–4.2 µg/ml shown in Table 1.
Compound Q5 exhibited mild antibacterial activity with MIC value in 
the range of (1.12 µg/ml) when compared to standard sparfloxacin 
Table 1: Antimicrobial activity of the synthesized compounds (Q1-Q10) (100 µg/ml)
Compounds In vitro activity - zone of inhibition in mm (MIC in µg/ml)
Gram-positive bacteria Gram-negative bacteria Fungi
S. aureus S. epidermidis E. coli K. pneumoniae A. niger A. fumigatus
Q1 28 (1.2) 25 (3.4) 23 (1.2) 24 (4.2) 18 (14.1) 23 (15.6)
Q2 29 (1.3) 24 (3.3) 26 (0.8) 24 (2.8) 19 (13.6) 24 (14.9)
Q3 29 (1.6) 26 (3.8) 26 (1.9) 22 (3.5) 17 (13.8) 23 (15.2)
Q4 30 (1.4) 26 (2.6) 30 (0.9) 31 (2.2) 18 (13.9) 20 (14.8)
Q5 32 (1.1) 31 (2.2) 22 (2.2) 20 (3.9) 23 (14.2) 23 (15.6)
Q6 32 (1.2) 28 (2.9) 23 (1.0) 22 (3.8) 21 (14.7) 21 (16.2)
Q7 24 (2.4) 24 (3.1) 27 (1.8) 24 (4.1) 25 (13.2) 25 (14.3)
Q8 21 (2.0) 25 (3.3) 29 (1.1) 27 (2.3) 25 (12.9) 24 (13.1)
Q9 29 (1.4) 27 (2.5) 28 (1.7) 26 (3.5) 26 (12.7) 27 (13.8)
Q10 28 (2.5) 21 (3.1) 28 (1.9) 23 (2.6) 22 (14.1) 21 (14.8)
Sparfloxacina 34 (0.7) 33 (0.8) 34 (0.2) 33 (0.1) - -
Ciprofloxacina 37 (0.5) 35 (0.12) 36 (0.06) 36 (0.06) - -
Ketoconazoleb - - - - 29 (10.8) 33 (11.4)
DMFc - - - - - -
Sparfloxacina, Ciprofloxacina: Standard antibacterial drugs, Ketoconazoleb: Standard antifungal drug and DMFc: Control. S. aureus: Staphylococcus aureus, S. epidermidis: 
Staphylococcus epidermidis, E. coli: Escherichia coli, K. pneumonia: Klebsiella pneumonia, A. niger: Aspergillus niger, A. fumigatus: Aspergillus fumigatus. MIC: Minimum 
inhibitory concentrations
Scheme 1: Synthesis of N-Piperzinyl derivatives of sparfloxacin
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(0.7 µg/ml) and ciprofloxacin (0.5 µg/ml). This mild antibacterial 
activity is maybe due to addition of new derivative dimethyl 
phenylamino group at the 7th position of piperzinyl ring.
Compound Q4 exhibited mild Gram-negative antibacterial with 
MIC values in the range of (0.9 µg/ml) when compared to standard 
sparfloxacin (0.2 µg/ml) and ciprofloxacin (0.06 µg/ml). This mild 
antibacterial activity is maybe due to the addition of new derivative 
nitromethyl benzoyl group at the 7th position of piperzinyl ring.
Antifungal activity
All the synthesized compounds (Q1-Q10) were tested zone of inhibition 
and MIC values against two fungi organisms (A. niger and A. fumigatus). 
All the compounds exhibited mild to moderate activity. Compounds Q9, 
Q8, and Q7 were found to possess significant antifungal activity against 
A. niger when compared to standard ketoconazole. Compounds Q9, Q2, 
and Q7 were found to possess significant antifungal activity against 
A. fumigatus when compared to standard drug ketoconazole. The 
synthesized compounds exhibited MIC values in the range of 12.7–
16.2 µg/ml shown in Table 1.
Compound Q9 exhibited mild antifungal activity with MIC values of 
(12.7 µg/ml) and (13.8 µg/ml) when compared to standard ketoconazole 
(10.8 µg/ml) and (11.4 µg/ml). This mild antifungal activity is maybe 
due to the addition of new derivative methyl oxopyrrolidine group at 
the 7th position of piperzinyl ring.
Table 2: Docking result of synthesized compounds (Q1-Q10) with MIC values (µg/ml)
Compounds Gram-positive bacteria (S. aureus) Gram-negative bacteria ( E. coli )
Docking 
Scorea
MIC (µg/ml) H bonds with 5IWM enzyme Docking 
Scorea
MIC (µg/ml) Interactions with 3FV5 
enzyme
Q1 −9.2 1.2 3rd position COOH oxygen with 
ALA138 and 5th position amino 
hydrogen with GLY963
−7.1 1.2 5th position amino hydrogen 
with ARG79
Q2 −9.2 1.3 5th position amino 
hydrogen with ASP475 
and methyl (methylamino) 
benzenesulfenyl amino 
hydrogen with ALA459
−7.2 0.8 5th position amino nitrogen 
with ILE81
Q3 −9.4 1.6 3rd position COOH Oxygen with 
GLY958 and Amino methyl 
benzoyl hydrogen with LYS28
−7.0 1.9 5th position amino hydrogens 
with ARG124 And ASP56 and 
nitrogen with THR126
Q4 −9.5 1.4 3rd position COOH hydrogen 
with GLY287, 5th position amino 
hydrogens with ALA275 and 
GLY287 nitromethyl benzoyl 
oxygen with ILE312
−7.6 0.9 Nitromethyl benzoyl oxygen 
forms hydrogen bond with 
ALA47
Q5 −9.8 1.1 3rd position COOH Oxygen with 
MET294, 5th position amino 
hydrogen with GLY292 and 
dimethyl phenylamino hydrogen 
with GLY287
−7.2 2.2 5th position amino hydrogen 
with THR126
Q6 −9.6 1.2 4th Position Oxygen with 
GLY958 and 5th position amino 
hydrogens with GLU997 and 
PRO365 and amino nitrogen 
with GLY958
−7.1 1.0 3rd position COOH hydrogen 
with GLY59
Q7 −8.8 2.4 5th position amino hydrogen 
with GLY958 and Dimethyl 
oxopyrazol oxygen with ILE983
−7.2 1.8 Dimethyl oxopyrazol oxygen 
with ILE81
Q8 −8.6 2.0 3rd position COOH oxygen with 
PHE962 and Methyl dioxo 
pyrrolidine Piperazine Oxygen 
with ILE1154
−7.4 1.1 Methyl dioxo pyrrolidine 
Piperazine oxygen with ILE81
Q9 −8.6 1.4 5th position amino hydrogen 
with GLY958 and 3rd position 
COOH oxygen with ALA138
−7.4 1.7 Methyl oxo pyrrolidine 
Piperazine oxygen with SER82
Q10 −8.2 2.5 3rd position COOH oxygen 
with SER22 and ASP21 
and Aminomethyl methyl 
pyrrolidine hydrogens with 
DA1349 and DG1369
−7.3 1.9 Aminomethyl 
methylpyrrolidine hydrogen 
with LEU75
Sparflo-xacinb −8.2 0.7 3rd position COOH oxygen with 
ALA970 and 5th position amino 
hydrogens with ASP968 and 
SER964
−7.2 0.2 3rd position COOH hydrogen 
with HIS37, 5TH Position amino 
nitrogen with THR126 and 
hydrogen with THR126
Ciproflo-xacinb −7.8 0.5 7th position Piperazine hydrogen 
with VAL1120 and 3rd position 
COOH oxygen with ALA790
−7.3 0.06 7th position Piperazine 
hydrogen with ASP56
aBased on Auto Dock Vina score, bSparfloxacin, ciprofloxacin (standard drugs). MIC: Minimum inhibitory concentrations, S. aureus: Staphylococcus aureus,  
E.Coli: Escheriachia coli
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Docking study
Molecular docking studies were employed for the analysis with 
a training set composed of our synthesized compounds whose 
inhibitory activity is unknown. To find out the molecular facilities 
responsible for biological activity molecular docking studies was 
performed. From the docking studies, we predicted that all the 
synthesized compounds (Q1-Q10) possess better antibacterial activity 
than the standard drugs (ciprofloxacin and sparfloxacin). By having 
good binding affinity with target protein, it could be used as a 
potential drug as antibacterial.
Gram-positive bacteria docking studies
Among all the docked compounds, Q5, Q6, Q4, and Q3 show good binding 
affinity and interaction with topoisomerase-II DNA gyrase enzyme 
(5IWM) with reference to standard drugs ciprofloxacin and sparfloxacin.
The interactions of H bonds with ligands and bacterial enzymes 
explained that Compound Q5 at 3rd position carboxylic oxygen forms 
hydrogen bond with MET294, 5th position amino functional group forms 
hydrogen bond with ALA275, 7th position piperzinyl ring attachment 
dimethyl phenylamino group, and one of the methyl group hydrogen 
forms hydrogen bond with GLY287 as shown in Fig. 3 and interactions 
are shown in Fig. 4.
Compound Q5 having higher dock score (−9.8) toward bacterial S. aureus 
enzyme than the standard ciprofloxacin (−7.8) and sparfloxacin (−8.2) 
drugs. We may declare that the higher docking score is due addition 
of dimethyl phenylamino group at the 7th position of sparfloxacin 
structure. The remaining compounds docking score and hydrogen bond 
interactions are described in Table 2.
Gram-negative bacteria docking studies
Among all the docked compounds, Q4, Q8, Q9, and Q10 show good binding 
affinity and interaction with topoisomerase-IV enzyme (3FV5) with 
reference to standard drugs ciprofloxacin and sparfloxacin.
Compound Q4 at 7th position piperzinyl ring attachment nitromethyl 
benzoyl oxygen forms hydrogen bond with ALA47 as shown in Fig. 5 
and interactions are shown in Fig. 4.
Compound Q4 is having higher affinity (−7.6) toward E. coli enzyme 
than the standard ciprofloxacin (−7.3) and sparfloxacin (−7.2) 
drugs. We may declare that the higher docking score is due addition 
Fig. 3: H-bonds interactions between compound (Q5) with 
topoisomerase-II DNA gyrase enzyme of Gram-positive 
Staphylococcus aureus bacteria (5IWM)
Fig. 7 Gram-negative (Escherichia coli) correlation plot between 
minimum inhibitory concentrations (µg/ml) and docking scores 
(Kcal/mol)
Fig. 5: H-bonds interactions between compound (Q4) with 
topoisomerase-IV enzyme of Gram-negative Escherichia coli 
bacteria (3FV5)
Fig. 6: Gram-positive (Staphylococcus aureus) correlation plot 
between minimum inhibitory concentrations (µg/ml) and 
docking scores (Kcal/mol)
Fig. 4: Two-dimensional ligand interaction diagram of compounds 
Q5 with DNA gyrase and Q4 with Escherichia coli, the amino acid 
residues at the binding site are tagged in circles
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of nitromethyl benzoyl group at the 7th position of sparfloxacin 
structure. The remaining compounds docking score and hydrogen 
bond interactions are described in Table 2. The correlation between 
experimental data (MIC) and docking score of S. aureus and E. coli is 
displayed 0.604 r2 and 0.071 r2 (Figs. 6 and 7) which suggests that 
parameters for docking simulation are good for S. aureus and mild 
for E. coli in reproducing experimental orientation of synthesized 
compounds.
CONCLUSION
We have synthesized and characterized 10 new derivatives of 
sparfloxacin. All the molecules were studied for their interactions 
with topoisomerase-II DNA gyrase and topoisomerase-IV enzymes by 
molecular docking protocol. Among the tested molecules, Compounds 
Q5, Q6, Q4, and Q3 exhibited good docking score for Gram-positive bacteria 
and Compounds Q4, Q8, Q9, and Q10 for Gram-negative bacteria. In vitro, 
antibacterial activity of tested compounds shows mild activity against 
microorganisms used. In particular, Compounds Q5, Q6, Q4, and Q3 possess 
significant Gram-positive activity and Compounds Q4, Q8, Q9, and Q10 
possess significant Gram-negative activity. The results of antibacterial 
activity are supported by docking analysis only for S. aureus.
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